Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297249 | 0.89 | KDM5A (0.54) | KDM4EMAPTTDP1KDM5AKDM5B | |
| SCHEMBL14065345 | 0.87 | GRIN2D (0.44) | RNASEH1MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL4286288 | 0.87 | GRIN2D (0.46) | RNASEH1MEN1KMT2AGRIN2DGRIN3B | |
| SCHEMBL5545845 | 0.86 | MEN1 (0.50) | RNASEH1MEN1KMT2ARXFP1ALDH1A1 | |
| SCHEMBL5546762 | 0.85 | MEN1 (0.48) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5547071 | 0.82 | KMT2A (0.48) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5545679 | 0.82 | MEN1 (0.64) | MEN1KMT2ARXFP1ALDH1A1KDM4E | |
| SCHEMBL5546807 | 0.81 | KMT2A (0.61) | MEN1KMT2ARXFP1ALDH1A1KDM4E | |
| SCHEMBL5545946 | 0.81 | NPC1 (0.57) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5545813 | 0.80 | NPC1 (0.56) | MEN1KMT2ARXFP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8691991-B2 | 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-8691991-B2 | 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| EP-1720856-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | RNASEH1 468/4885MEN1 4802/4885KMT2A 502/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | RNASEH1 1169/4885MEN1 4837/4885KMT2A 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.